Background and Aim: Crohn's disease [CD] is a progressive inflammatory bowel disease that can lead to complications such as strictures or penetrating disease, and ultimately surgery. Few population-based studies have investigated the predictors for disease progression and surgery in CD according to the Montreal classification. We aimed to identify clinical predictors associated with complicated CD in a Danish population-based inception cohort during the biologic era. Conclusions: This population-based inception cohort study demonstrates that changes in disease location or behaviour in patients with CD increase their risk of resection. Our findings highlight the protective effect of biologic treatment with regard to change in disease location, which might ultimately improve the disease course for CD patients.
Introduction
Crohn's disease [CD] is an inflammatory bowel disease [IBD] that may involve the whole gastrointestinal tract. CD is a progressive and dynamic disease. 1 Around 5-24% 2-4 of patients experience a change in disease location and 16-17% experience a worsening in disease behaviour within the first 5 years of diagnosis, including the development of intestinal strictures, abscesses, or fistulas. 3, 5 Progression in behaviour is associated with a need for more intensive medical treatment [eg. high doses of corticosteroids, treatment with immunosuppressive medications, or biologics] or surgical interventions, and ultimately a substantial reduction in quality of life. 6 Several predictors for a change in disease location or progression in disease behaviour have been identified, including ileal or ileocolonic disease location, severe upper gastrointestinal disease, young age at diagnosis, and smoking. [7] [8] [9] However, these predictors remain contentious and contradictions occur in the literature, and only limited data are available from the era of biologic treatments. 10 It is therefore important to assess the risk of disease progression and identify predictors associated with worsening disease behaviour.
Population-based inception cohorts are considered the gold standard among epidemiological studies for better approximating the entire patient population and avoiding selection bias. We have previously reported on the disease course and risk of surgery in IBD patients in a population-based prospective cohort from Denmark. 5 The aim of this study was to identify clinical predictors associated with changes in disease behaviour and location, and the subsequent risk of surgical interventions, in a Danish population-based prospective cohort of CD patients in the era of biologic treatments.
Materials and Methods

Patient population
Between January 1, 2003 and December 31, 2004, all incident patients diagnosed with CD, ulcerative colitis, or inflammatory bowel disease unclassified [IBDU] , in a well-defined Copenhagen region, were prospectively included in a population-based inception cohort. Registration and follow-up have been described previously. 5, 11 The uptake area included a background population of 1 211 634 residents, corresponding to 23% of the total population of Denmark. The corresponding incidence rate of 8.8 per 100 000 people is similar to the incidence rate for the country as a whole. 11, 12 Patients were followed from the date of diagnosis until December 31, 2011, ensuring a follow-up period of at least 7 years. Clinical data including demographics, surgery and hospitalisation rates, investigations, medical therapy, and changes in disease classification were registered and re-evaluated throughout the follow-up period. Patients who emigrated or died were excluded from the study on the day of migration or death. Details regarding the re-evaluation have been described previously. 5 Any prescriptions or changes in medication during the follow-up period were documented in the patient's records, according to Danish regulations. Complete data capture regarding surgical procedures for the entire study group was ensured by linking the patients' unique 10-digit personal identification number to the National Patient Registry, 13 which contains information on diagnosis codes and surgical procedures. A comparison with the surgical procedure registry was performed by cross-matching codes for resection and colectomy [KJFB00 -97, KJFHH00 -96] with codes for IBD [K50.0 -K51.9].
Diagnosis and definition
The diagnosis of CD was based on the Copenhagen Diagnostic Criteria.
14 Disease location and behaviour were initially defined according to the Vienna classification. 15 For this study, all patients were reviewed and re-categorised according to the Montreal classification, 16 both at diagnosis and throughout the follow-up period. Accordingly, age at diagnosis was categorised as: A1: < 17 years; A2: 17-40 years; and A3: > 40 years. Disease location [L] was defined as: L1: terminal ileum; L2: colon; L3: ileocolon; and L4: upper gastrointestinal tract, the latter also acting as a modifier in patients with proximal disease in conjunction with distal disease [L1 to L3]. Due to the low number of patients with upper gastrointestinal tract involvement, all such patients were categorised as L4. Patients were categorised as: B1 if they had a non-stricturing, non-penetrating disease; B2 if the disease was stricturing; and B3 if the disease was penetrating [excluding those with perianal fistula/abscess]. Phenotype progression was defined as the development of B2 or B3 in patients with B1 at diagnosis.
Disease location and behaviour, as well as changes in these parameters during the follow-up period, were assessed using standard investigative procedures including endoscopy, magnetic resonance imaging [MRI] , computerised tomography [CT], barium X-ray, and ultrasound. All procedures were performed at the treating physician's discretion. In cases where no investigative procedures were performed before intestinal surgery, macroscopic description of the surgical specimen was used to describe the behaviour and location of the disease. Smoking habits were recorded at the time of diagnosis. Smoking was defined as daily consumption of tobacco for at least the preceding 6 months, and was stratified as 'ongoing smoker', 'former smoker', and 'never smoker'. Diagnostic delay was defined as the number of days between onset of symptoms and diagnosis.
Treatment was categorised according to five levels of ascending therapeutic potency: 5-aminosalicylates [5- 
Treatment policy
The treatment regimen for IBD in Copenhagen during the followup period was based on Danish IBD guidelines, which agree with European [European Crohn's and Colitis Organisation], British [British Society of Gastroenterology], and American [American Gastroenterological Association] guidelines. Systemic [and topical] corticosteroids were used to treat flare-ups and immunosuppressants were used as maintenance therapy. In moderate to severe cases, a high dose of corticosteroid, defined as ≥ 50 mg prednisolone, was usually administered as 1 mg/kg. Infliximab was approved as a treatment for CD in 1999, and adalimumab in 2003, in Denmark.
Statistical analysis
All statistical analyses were performed in RStudio (RStudio Team [2016] ; RStudio: Integrated Development for R; RStudio, Inc., Boston, MA; URL: [http://www.rstudio.com/]). Data are given as numbers, percentages, means, and standard deviations [SD] . Associations between progression and change of behaviour and location, resection, and fistula development, along with multiple covariates [age, gender, smoking status, diagnostic delay, initial disease behaviour, initial disease location, change in disease location, and treatment with CS within 1 year and biologics within 2 years] at diagnosis, were examined with Cox regression analysis using the proportional hazard assumption. The risks of resection and development of fistula were assessed in all CD patients, and the risk of a change in disease behaviour was assessed in CD patients initially classified as B1. A p-value of < 0.05 was considered statistically significant.
The 
Results
A total of 213 patients fulfilled the diagnostic criteria for CD and were included in the study. The median follow-up time was 7.7 years (interquartile range [IQR] 7.1-8.4). Patient characteristics are shown in Table 1 . Figures 1 and 2 .
Change in disease location and behaviour
Of those patients diagnosed with B1, 31 [18%] progressed to either B2 or B3. The cumulative risk of progression is shown in Figure 3 . After 1 year the risk was 3%, after 5 years it was 14%, and after 7 years it was 16%. Most of these 31 patients were A2 (A1: 
Risk of perianal fistula and abscesses
In total, 30 [14%] patients developed either a perianal fistula or abscess. The cumulative risk of developing a perianal fistula or abscess is shown in Figure 3 . After 1 year the risk was 9%, after 5 years it was 13%, and after 7 years it was 15%. Predictors associated with perianal fistula and abscesses are shown in Table 2 . Predictors associated with resection in patients diagnosed with B1 are shown in Table 2 .
Risk of resection
Discussion
We have shown that in an unselected, population-based, inception cohort of CD cases in Copenhagen, Denmark, a change in disease behaviour or location increased the risk of surgery. One-quarter of patients presented a change in disease location during the follow-up peroid, and 18% progressed from B1 to B2/B3. Interestingly, patients experiencing a change in location or a progression in their disease behaviour had a significantly higher cumulative risk of resection as compared with those not experiencing a change in location or progression in behaviour. Over time, those initially diagnosed with B1 who progressed in behaviour had a risk of resection comparable to those who were initially diagnosed with B2 [ Figure 3] .
Previous reports have shown that 5-25% of all B1 patients experience disease progression during the first 5 years after diagnosis. [17] [18] [19] [20] [21] [22] [23] [24] Compared with the literature, our findings favour the lower end of that range; however, only a few inception cohort studies have addressed this topic. [19] [20] [21] [22] [23] [24] The low rate of progression might be a reflection of the population-based nature of the cohort. Furthermore, Denmark's universal health care system and the trust placed in it ensure that all patients have access to the full range of investigative procedures and treatments and that the quality of treatment and follow-up is generally high. To our knowledge, clinical predictors specifically associated with progression from B1 have not previously been investigated in population-based cohorts, nor has the rate of resection among patients initially diagnosed with B1. Our study confirms that ileal disease location and a stricturing phenotype significantly increase the risk of surgery. 7 It is noteworthy that smoking at diagnosis was not associated with resection in our study. A recent meta-analysis found that smokers have a more complicated disease course [surgery and/or flare-ups], 9 although the majority of the studies included were not carried out in well-defined populationbased cohorts, which might explain why it was not a significant factor in our study. 25, 26 Interestingly, we found that biologic treatment had a protective effect against disease changing location, but at the same time was associated with progression in behaviour as well as surgery. Patients who received biologic therapy [a known risk factor for progression in behaviour and surgery] did not have a higher prevalence of ileal disease than those who did not receive biologics, but they did have a higher prevalence of penetrating disease and a lower prevalence of strictures. Data regarding disease activity were not available for this study and hence we cannot exclude the possibility that the association of biologic therapy with progression and surgery is due to the selection of patients receiving this treatment.
To our knowledge, the apparent protective effect of biologic treatment on change in disease location has not been observed previously. The ability of biologic therapy to prevent structural bowel damage in CD in the long term has thus far not been demonstrated in population-based cohorts. 24 Our finding, however, suggests that biologics might prevent a change in location and the extent of disease, and thereby the disease course, in CD patients. However, whether the adoption of earlier and more aggressive treatment strategies improves long-term outcomes needs to be confirmed by larger prospective studies. 27 In the present cohort, one should note that during the early follow-up period, the use of biologic treatment was prescribed conservatively, often used as an on-demand treatment according to the early treatment strategies, and this might have impacted on the disease course. The use of biologics increased throughout the follow-up period. 5 At this point, no validated models for prediction of complicated disease course are available. Unfortunately, clinical predictors are not modifiable, and biological markers are needed as risk factors to better predict complicated disease course. Using clinical characteristics in combination with serological and genetic profiles to predict disease course might potentially help to identify patients in need of more aggressive treatment, but future studies are needed to validate this possibility. 28, 29 The main strength of the present study is its design. A welldefined population-based inception cohort is considered the gold standard in epidemiology and avoids selection bias by representing the whole spectrum of disease severity. Patient records were re-evaluated, and patients fulfilling the previously described criteria were included in the study, thereby diminishing any bias arising from original misdiagnosis. The personalised 10-digit registration number, unique to all Danish patients, enabled us to cross-check with the National Patient Registry to ensure complete follow-up of medical treatment and surgery. We have previously reported on the disease course, including the risk of surgery, in CD patients in this cohort. 5 However, because of the quality of the available data, we performed an in-depth analysis of specific changes in the Montreal classification and the impact on risk of surgery, which was not addressed in the previous report.
The limitations of this study include the fact that patients were classified according to the Vienna classification at baseline and then had to be re-classified according to the Montreal classification for this study. During this re-classification, those initially classified as B3 because of perianal fistula were reclassified as either B1 or B2 according to the Montreal classification. Misclassification during this process might have occurred, but it is our belief that the likelihood of this is negligible because data on perianal fistula were registered during follow-up. Furthermore, the findings in this study might not be fully transferable to other countries and regions, due to the high quality of and free access to the Danish health care system.
In conclusion, this study demonstrates that a change in disease location, or progression in disease behaviour, significantly increases the risk of a surgical resection in a population-based inception cohort of IBD patients. Biologic treatment had a protective role in changing disease location and could thereby potentially be used to improve the natural disease course and risk of surgery. Progression from inflammatory behaviour increases the risk of surgery significantly to a level comparable to those diagnosed with stricturing disease in the first place. Our findings highlight the need for preventing changes in disease location and progression in disease behaviour, as well as the need to identify biological markers that might stratify patients based on the risk of their disease changing location and progressing in behaviour.
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